Project 3: Translational Studies and Clinical Pharmacology of TLR4 and TOPK Signaling Pathway Inhibitors for Prevention of Squamous Cell Carcinoma of the Skin
项目3:TLR4和TOPK信号通路抑制剂预防皮肤鳞状细胞癌的转化研究和临床药理学
基本信息
- 批准号:10252871
- 负责人:
- 金额:$ 22.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-10 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:Actinic keratosisAcuteAdultAgeArchivesBehavioralBiological AvailabilityBiological MarkersBromidesCancer EtiologyCharacteristicsChemopreventionChronicClinicalClinical PharmacologyCollaborationsCollectionCutaneousDevelopmentDrug TargetingDysplasiaExposure toFormulationFunding MechanismsGeneral PopulationGoalsHealth Care CostsHumanHuman VolunteersImmunohistochemistryIncidenceIndividualInterventionKRP proteinLeadLesionLightLinkLymphokine-Activated Killer CellsMalignant NeoplasmsModelingMorbidity - disease rateMusPathway interactionsPatientsPharmaceutical PreparationsPharmacodynamicsPharmacologyPhasePhosphoproteinsPhototherapyPopulationPrevalencePreventionPreventivePreventive MedicineProcessProtein Activation PathwayProtein Array AnalysisProtein KinaseProtein Microarray AssayProtein MicrochipsProteinsRiskSafetySamplingSignal PathwaySignal TransductionSkinSkin CancerSkin CarcinogenesisSkin CarcinomaSocietiesStandardizationStressSun ExposureTLR4 geneTP53 geneTestingThe SunTherapeuticTopical agentTopical applicationUV Radiation ExposureUV inducedUltraviolet Raysaging populationbasecancer chemopreventioncarcinogenesiscarcinogenicityclinical developmentclinical efficacyclinically relevantcohorteffective interventionefficacious interventionexposed human populationinhibitor/antagonistinterestkeratinocytelaser capture microdissectionmortalitymultidisciplinarynetwork architecturenovelnovel therapeuticspatient populationpersonalized medicinephase 1 studyphase 2 studyphase I trialpre-clinicalpreventive interventionprospectiveprotein kinase inhibitorresponseskin cancer preventionskin damageskin squamous cell carcinomasmall moleculesmall molecule inhibitorsun damagesun protectiontranslational study
项目摘要
ABSTRACT
Project 3 (Curiel,Chow) Translational Studies and Clinical Pharmacology of TLR4 and TOPK Signaling
Pathway Inhibitors for Prevention of Squamous Cell Carcinoma of the Skin
One out of three new cancers is a skin cancer, making skin cancer the most common malignancy worldwide.
Approximately 5 million cases of non-melanoma skin cancer (NMSC) occur annually in the US. Cutaneous
squamous cell carcinoma (cSCC) represents 20-25% of all NMSC. The incidence of cSCC is expected to
continue to increase as the population ages and behavioral barriers to sun protection persist. Therefore, there
is an increasing and substantial impact to society on morbidity and health care costs associated with NMSC
($8.1 billion/year) and actinic keratoses (AK) (preneoplastic cSCC lesions; > 1 billion/year).
The overall goal of this project is to determine the clinical relevance of Toll-like Receptor 4 (TLR4) and T-LAK
cell-originated protein kinase (TOPK) / p53-related protein kinase (PRPK) signaling pathways in ultraviolet light
induced human skin carcinogenesis process leading to cSCC development. Furthermore, we propose to
develop effective pharmacological small molecule inhibitors of these pathways to etsablish a personalized
medicine approach to this population in need of more effective intervention in the prevention setting. The
hypothesis for this project is that TOPK/ PRPK and TLR4 drive UV-induced carcinogenic signaling pathways in
human skin, which can be pharmacologically targeted for effective topical prevention of cutaneous cSCC. Our
approach to validate the encouraging preclinical results presented in projects 1 and 2 in chronically UV
exposed human skin includes the assessment of the activation state of these pathways in our robust archive
and prospective collection of clinically annotated matched human samples ranging from sun protected skin
(SP), sun damaged (SD), AK, to cSCC (Aim 1). The protein/phosphoprotein network architecture for TLR4 and
TOPK/PRPK will be assessed through IHC and reverse phase protein microarray (RPPA) analysis. Ultimately
we envision to identfy a subset of biomarkers by IHC that can allow us to accurately select the cohort of
patients that will benefit from a targeted intervention using one of the small molecule inhibitors proposed in this
application. To asses the modulatory effect of the proposed inhibitors in human skin we are using a
standardized acute solar simulated light (SSL) model (Aim 2). As part of this effort we will be evaluating the
effect of acute SSL exposure on the pathways of interest using SD skin (Aim 2a). Susbsequently, small
molecule inhibitors will be introduced to the acute human SSL model to determine direct targeted effects (Aim
2b). Our final aim will assess safety and phamacodynamics of the proposed TLR4 or TOPK/PRPK small
molecule inhibitors in a Phase 1 study (Aim 3).
This multidisciplinary translational proposal focuses on the novel identification of complementary cellular
signaling network and their relationship with other established pathways in skin carcinogenesis, to guide the
selection and early clinical development of targeted topical small molecule inhibitors. This will facilitate a
personalized based approach for the therapeutic prevention of cSCC.
摘要
项目3(Curiel,Chow)TLR 4和TOPK信号转导的转化研究和临床药理学
预防皮肤鳞状细胞癌的途径抑制剂
三分之一的新癌症是皮肤癌,使皮肤癌成为世界上最常见的恶性肿瘤。
在美国,每年发生约500万例非黑色素瘤皮肤癌(NMSC)。皮肤
鳞状细胞癌(cSCC)占所有NMSC的20-25%。预计cSCC的发病率
随着人口老龄化和防晒行为障碍的持续存在,因此
对NMSC相关的发病率和医疗保健费用的社会影响越来越大
($81亿/年)和光化性角化病(AK)(癌前cSCC病变; > 10亿/年)。
本项目的总体目标是确定Toll样受体4(TLR 4)和T-LAK的临床相关性
紫外光下的细胞源蛋白激酶(TOPK)/ p53相关蛋白激酶(PRPK)信号通路
诱导人类皮肤癌变过程,导致cSCC的发展。此外,我们建议
开发这些途径的有效药理学小分子抑制剂,以建立个性化的
在预防环境中,需要对这一人群采取更有效的干预措施。的
该项目假设是TOPK/ PRPK和TLR 4驱动UV诱导的致癌信号通路,
人皮肤,其可被靶向用于有效局部预防皮肤cSCC。我们
一种方法来验证项目1和2中提出的令人鼓舞的临床前结果,
暴露的人类皮肤包括在我们强大的档案这些途径的激活状态的评估
和前瞻性收集临床注释的匹配人类样本,
(SP)日晒损伤(SD),AK,至cSCC(Aim 1)。TLR 4的蛋白质/磷蛋白网络结构,
TOPK/PRPK将通过IHC和反相蛋白微阵列(RPPA)分析进行评估。最终
我们设想通过免疫组化鉴定生物标志物的子集,使我们能够准确地选择
患者将受益于使用本研究中提出的一种小分子抑制剂的靶向干预,
应用程序.为了评估所提出的抑制剂在人体皮肤中的调节作用,我们使用了
标准化急性太阳模拟光(SSL)模型(Aim 2)。作为这项工作的一部分,我们将评估
急性SSL暴露对使用SD皮肤的感兴趣途径的影响(目标2a)。小尺寸
将分子抑制剂引入急性人SSL模型以确定直接靶向效应(Aim
2b)。我们的最终目的是评估所提出的TLR 4或TOPK/PRPK小分子的安全性和药效学。
1期研究中的分子抑制剂(目标3)。
这个多学科的翻译建议集中在新的识别互补的细胞
信号网络及其与其他已建立的皮肤癌发生途径的关系,以指导
靶向局部小分子抑制剂的选择和早期临床开发。这将有助于A
基于个性化的方法用于治疗性预防cSCC。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Clara Curiel-Lewandrowski其他文献
Clara Curiel-Lewandrowski的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Clara Curiel-Lewandrowski', 18)}}的其他基金
Project 3: Translational Studies and Clinical Pharmacology of TLR4 and TOPK Inhibitors for Prevention of Squamous Cell Carcinoma of the Skin
项目3:TLR4和TOPK抑制剂预防皮肤鳞状细胞癌的转化研究和临床药理学
- 批准号:
10410014 - 财政年份:2019
- 资助金额:
$ 22.78万 - 项目类别:
Targeted Prevention for Non-Melanoma Skin Cancer
非黑色素瘤皮肤癌的针对性预防
- 批准号:
10015212 - 财政年份:2019
- 资助金额:
$ 22.78万 - 项目类别:
Project 3: Translational Studies and Clinical Pharmacology of TLR4 and TOPK Signaling Pathway Inhibitors for Prevention of Squamous Cell Carcinoma of the Skin
项目3:TLR4和TOPK信号通路抑制剂预防皮肤鳞状细胞癌的转化研究和临床药理学
- 批准号:
10475143 - 财政年份:2019
- 资助金额:
$ 22.78万 - 项目类别:
Targeted Prevention for Non-Melanoma Skin Cancer
非黑色素瘤皮肤癌的针对性预防
- 批准号:
10410013 - 财政年份:2019
- 资助金额:
$ 22.78万 - 项目类别:
Project 3: Translational Studies and Clinical Pharmacology of TLR4 and TOPK Signaling Pathway Inhibitors for Prevention of Squamous Cell Carcinoma of the Skin
项目3:TLR4和TOPK信号通路抑制剂预防皮肤鳞状细胞癌的转化研究和临床药理学
- 批准号:
10015218 - 财政年份:2019
- 资助金额:
$ 22.78万 - 项目类别:
相似海外基金
Un/kindness, shame & resistance: the care of inpatients in NHS adult acute mental health units and how it might be improved
Un/善良,羞耻
- 批准号:
2885806 - 财政年份:2023
- 资助金额:
$ 22.78万 - 项目类别:
Studentship
Post-Acute Care Transitions for Older Adult Medicare Beneficiaries with Serious Mental Illness
患有严重精神疾病的老年医疗保险受益人的急性后护理过渡
- 批准号:
10772386 - 财政年份:2023
- 资助金额:
$ 22.78万 - 项目类别:
Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)
通过 CAR-T 细胞疗法为加拿大护理标准铺平道路:CD19 CAR-T 治疗复发/难治性成人急性淋巴细胞白血病的 II 期试验 (CLIC-01A)
- 批准号:
474619 - 财政年份:2022
- 资助金额:
$ 22.78万 - 项目类别:
Operating Grants
Investigating the impact acute inhalation of cannabis with a high content of delta-9-tetrahydrocannabinol has on myelination and microglia in adult and aged mice
研究急性吸入高含量 delta-9-四氢大麻酚的大麻对成年和老年小鼠髓鞘形成和小胶质细胞的影响
- 批准号:
485965 - 财政年份:2022
- 资助金额:
$ 22.78万 - 项目类别:
Studentship Programs
Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)
通过 CAR-T 细胞疗法为加拿大护理标准铺平道路:CD19 CAR-T 治疗复发/难治性成人急性淋巴细胞白血病的 II 期试验 (CLIC-01A)
- 批准号:
466358 - 财政年份:2022
- 资助金额:
$ 22.78万 - 项目类别:
Operating Grants
Metabolomics for prediction of cisplatin mediated acute kidney injury: a Canadian multi-centre adult and pediatric study
预测顺铂介导的急性肾损伤的代谢组学:加拿大多中心成人和儿童研究
- 批准号:
402040 - 财政年份:2019
- 资助金额:
$ 22.78万 - 项目类别:
Operating Grants
Study of pathogenic mechanism of age-dependent chromosome translocation in adult acute lymphoblastic leukemia
成人急性淋巴细胞白血病年龄依赖性染色体易位发病机制研究
- 批准号:
18K16103 - 财政年份:2018
- 资助金额:
$ 22.78万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Causal effect of time-varying driving pressures on mortality in mechanically ventilated, adult patients with acute respiratory distress syndrome
时变驱动压力对机械通气成年急性呼吸窘迫综合征患者死亡率的因果影响
- 批准号:
377313 - 财政年份:2017
- 资助金额:
$ 22.78万 - 项目类别:
Studentship Programs
Role of SETBP1 in adult Ph+ acute lymphoblastic leukemia
SETBP1 在成人 Ph 急性淋巴细胞白血病中的作用
- 批准号:
9315111 - 财政年份:2016
- 资助金额:
$ 22.78万 - 项目类别:
Acute Inhibition of Adult-born Granule Cells and its Effect on Antidepressant Act
成体颗粒细胞的急性抑制及其抗抑郁作用
- 批准号:
8734273 - 财政年份:2013
- 资助金额:
$ 22.78万 - 项目类别: